ORIL’s strategy is to aggressively seek intellectual property protection on proprietary technologies where the scientific, business and legal support for such protection are soundly based. The technology is 100% owned by the Company. To date 4 patent families have been granted or are pending in national phase entry with a number of other patent applications being drafted. The Company has also filed “Composition of Matter” patent protection for its process of a physical form of ORIL007 that provides the same efficacious properties of plant-extracted ORIL007, but with superior physical characteristics for stability, formulation and materials handling.
Registered Office
Oncology Research International Limited
Level 5, 45 St George Terrace,
Perth WA 6000 Australia